The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme.
Open accessAbstract
OBJECTIVE--To examine the relation between the use of aspirin and non-steroidal anti-inflammatory drugs and the presence of asymptomatic colorectal adenomas. DESIGN--Case-control study of subjects participating in a randomised controlled trial of faecal occult blood screening for colorectal cancer. Data on analgesics and other drugs were obtained from a questionnaire which was mainly concerned with diet and was administered by an interviewer. SETTING--Nottingham. SUBJECTS--147 patients with positive results in faecal occult blood tests who were found to have colorectal adenomas (cases), 153 age and sex matched control subjects with negative results in such tests (negative controls), and 176 control subjects with positive results in the tests who were found not to have colorectal adenomas (positive controls). MAIN OUTCOME MEASURES--Relative risk of developing colorectal adenomas according to frequency and duration of use of analgesics. RESULTS--Cases reported taking less aspirin and non-steroidal anti-inflammatory drugs than the negative controls, with the estimated relative risk for any use being 0.49 (95% confidence interval 0.3 to 0.8). The inverse association was less strong when cases were compared with the positive controls (0.66 (0.4 to 1.1)). The association was specific for aspirin and non-steroidal anti-inflammatory drugs there being no association with paracetamol or other drugs. Prescribed use of non-steroidal anti-inflammatory drugs for longer than five years was associated with the lowest risk (0.21 (0.1 to 0.8)), although the numbers reporting prolonged prescribed use were small. CONCLUSIONS--These findings support the hypothesis that aspirin and non-steroidal anti-inflammatory drug use protects against the development of colorectal neoplasia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717
Aspirin Use and Reduced Risk of Fatal Colon Cancer
Thun, M. J., Namboodiri, M. M., & Heath, C. W. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252301 · Cited by 1,673
Sulindac causes regression of rectal polyps in familial adenomatous polyposis
Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., & Attali, P. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90519-q · Cited by 719
Kune, G. A., Kune, S., & Watson, L. F. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym193 · Cited by 654
RANDOMISED, CONTROLLED TRIAL OF FAECAL OCCULT BLOOD SCREENING FOR COLORECTAL CANCER
Hardcastle, J. D., Chamberlain, J., Sheffield, J., Balfour, T. W., Armitage, N. C., Thomas, W. M., Pye, G., James, P. D., Amar, S. S., & Moss, S. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92750-5 · Cited by 529
Self-citationSulindac for polyposis of the colon
Waddell, W. R., & Loughry, R. W. (1983) · Journal of Surgical Oncology · doi:10.1002/jso.2930240119 · Cited by 513
A Hypothesis: Nonsteroidal Anti-Inflammatory Drugs Reduce the Incidence of Large-Bowel Cancer
Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Stolley, P. D., & Shapiro, S. (1991) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/83.5.355 · Cited by 501
Kune, G. A., Kune, S., & Watson, L. F. (1988) · PubMed · Cited by 352
Reddy, B. S., Maruyama, H., & Kelloff, G. V. (1987) · PubMed · Cited by 302
Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment.
Narisawa, T., Sato, M., Tani, M., Kudo, T., Takahashi, T., & Goto, A. (1981) · PubMed · Cited by 226
Cited by
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,136
Aspirin and the Risk of Colorectal Cancer in Women
Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331001 · Cited by 1,090
Colorectal Cancer: Molecules and Populations
Potter, J. D. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.916 · Cited by 881
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I)
Taketo, M. M. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1529 · Cited by 757
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 723
Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Colorectal cancer prevention in ulcerative colitis: a case‐control study
Eaden, Abrams, Ekbom, Jackson, & Mayberry (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00698.x · Cited by 577
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Ulrich, C. M., Bigler, J., & Potter, J. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1801 · Cited by 548
Prostaglandin endoperoxide synthase: why two isoforms?
Williams, C. S., & DuBois, R. N. (1996) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1996.270.3.g393 · Cited by 455
Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M., Zimmerman, G. A., White, R. L., & Prescott, S. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4816 · Cited by 449
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Epidemiology of colorectal cancer
Boyle, P., & Leon, M. E. (2002) · British Medical Bulletin · doi:10.1093/bmb/64.1.1 · Cited by 437
Modifiable risk factors for colon cancer
Giovannucci, E. (2002) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(02)00057-2 · Cited by 423
Eicosanoids and the gastrointestinal tract
Eberhart, C. E., & Dubois, R. N. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90296-1 · Cited by 414
Comorbidities in rheumatoid arthritis
Michaud, K., & Wolfe, F. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.06.002 · Cited by 400
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II)
Taketo, M. M. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1609 · Cited by 399
Botanicals in Cancer Chemoprevention
Jung Park, E., & Pezzuto, J. M. (2002) · Cancer and Metastasis Reviews · doi:10.1023/a:1021254725842 · Cited by 380
Colorectal Cancer and Nonsteroidal Anti-inflammatory Drugs
Smalley, W. E., & DuBois, R. N. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60067-8 · Cited by 356
Rostom, A., Dubé, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00010 · Cited by 343
Dubé, C., Rostom, A., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00009 · Cited by 334
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080097 · Cited by 322
Nonsteroidal Anti-Inflammatory Drugs and Cancer Prevention
Baron, J. A., & Sandler, R. S. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.511 · Cited by 297
Peroxisome Proliferators Enhance Cyclooxygenase-2 Expression in Epithelial Cells
Meade, E. A., McIntyre, T. M., Zimmerman, G. A., & Prescott, S. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8328 · Cited by 293
The Role of Inflammation in Colon Cancer
Janakiram, N. B., & Rao, C. V. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_2 · Cited by 151
Metadata
- Authors
- Logan, R. F., Little, J., Hawtin, P. G., & Hardcastle, J. D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1993-07-31
- Volume
- 307
- Issue
- 6899
- Pages
- 285-289
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1968890157
- Cited by
- 264
- References
- 20
- FWCI
- 20.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.